Stephen Squinto, recruited by JP Morgan a few years ago to head up its Life Sciences Private Capital team, is raising a ...

The head of AstraZeneca’s operations in China has been detained by authorities there, the company confirmed. Prior to his ...

Gilead said its Covid-19 antiviral Veklury had $692 million in third-quarter sales, far more than the $270 million Wall ...

Moderna revealed the consequences of its late start in the market for RSV vaccines, reporting just $10 million in third-quarter sales from the new shot. Those numbers are a fraction ...

Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Coherus is resuming the supply of its ...

Aurinia Pharmaceuticals is reducing 45% of its workforce and is bringing in a new board member as part of a broader restructuring. The company ...

Plus, news about ADC Therapeutics, Celldex and Viracta Therapeutics: Geron inks up to $375M royalty and debt deal: The company now has a $125 million deal ...

Denali revealed new topline data Wednesday for an early-stage program that's a part of the FDA’s Operation Warp Speed for rare diseases. The program, DNL126, is an ...

Sarepta Therapeutics is stopping development of vesleteplirsen, an experimental exon 51-skipping therapy for Duchenne muscular dystrophy patients with certain mutations. It's also halting work on all ...

Joe Jimenez's Aditum Bio, an investment firm that builds companies around in-licensed assets, is going after one of the hottest new areas for its latest startup. The Oakland, CA-based firm ...

While there’s a lot of potential for AI in health tech, it will soon be commoditized, investor Greg Yap told Endpoints News in an interview on the sidelines of the ...

After a year of customer pullbacks, biologics CDMO Avid Bioservices will be taken private by GHO Capital Partners and Ampersand Capital Partners in a deal worth $1.1 billion. “In evaluating ...